|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.
|
|
2
|
Songun I, Putter H, Kranenbarg EM, Sasako
M and van de Velde CJ: Surgical treatment of gastric cancer:
15-year follow-up results of the randomised nationwide Dutch D1D2
trial. Lancet Oncol. 11:439–449. 2010.
|
|
3
|
Jain VK, Cunningham D and Chau I:
Preoperative and postoperative chemotherapy for gastric cancer.
Surg Oncol Clin N Am. 21:99–112. 2012.
|
|
4
|
Pasini F, Fraccon AP and DE Manzoni G: The
role of chemotherapy in metastatic gastric cancer. Anticancer Res.
31:3543–3554. 2011.
|
|
5
|
Lebwohl D and Canetta R: Clinical
development of platinum complexes in cancer therapy: an historical
perspective and an update. Eur J Cancer. 34:1522–1534. 1998.
|
|
6
|
Monneret C: Platinum anticancer drugs.
From serendipity to rational design. Ann Pharm Fr. 69:286–295.
2011.
|
|
7
|
Kang YK, Kang WK, Shin DB, et al:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: a
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009.
|
|
8
|
Koizumi W, Tanabe S, Saigenji K, et al:
Phase I/II study of S-1 combined with cisplatin in patients with
advanced gastric cancer. Br J Cancer. 89:2207–2212. 2003.
|
|
9
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al; V325 Study Group. Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.
|
|
10
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006.
|
|
11
|
Rennicke A, Voigt W, Mueller T, et al:
Resistance mechanisms following cisplatin and oxaliplatin treatment
of the human teratocarcinoma cell line 2102EP. Anticancer Res.
25:1147–1155. 2005.
|
|
12
|
Timmer-Bosscha H, Mulder NH and de Vries
EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a
review. Br J Cancer. 66:227–238. 1992.
|
|
13
|
Chun KH, Kosmeder JW II, Sun S, et al:
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt
pathway and apoptosis in premalignant human bronchial epithelial
cells. J Natl Cancer Inst. 95:291–302. 2003.
|
|
14
|
Lee HY, Oh SH, Woo JK, et al:
Chemopreventive effects of deguelin, a novel Akt inhibitor, on
tobacco-induced lung tumorigenesis. J Natl Cancer Inst.
97:1695–1699. 2005.
|
|
15
|
Murillo G, Salti GI, Kosmeder JW II,
Pezzuto JM and Mehta RG: Deguelin inhibits the growth of colon
cancer cells through the induction of apoptosis and cell cycle
arrest. Eur J Cancer. 38:2446–2454. 2002.
|
|
16
|
Ji BC, Yu CC, Yang ST, et al: Induction of
DNA damage by deguelin is mediated through reducing DNA repair
genes in human non-small cell lung cancer NCI-H460 cells. Oncol
Rep. 27:959–964. 2012.
|
|
17
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.
|
|
18
|
Choi MK and Kim DD: Platinum transporters
and drug resistance. Arch Pharm Res. 29:1067–1073. 2006.
|
|
19
|
Howell SB, Safaei R, Larson CA and Sailor
MJ: Copper transporters and the cellular pharmacology of the
platinum-containing cancer drugs. Mol Pharmacol. 77:887–894.
2010.
|
|
20
|
Olaussen KA, Mountzios G and Soria JC:
ERCC1 as a risk stratifier in platinum-based chemotherapy for
nonsmall-cell lung cancer. Curr Opin Pulm Med. 13:284–289.
2007.
|
|
21
|
Saldivar JS, Wu X, Follen M and Gershenson
D: Nucleotide excision repair pathway review I: implications in
ovarian cancer and platinum sensitivity. Gynecol Oncol. 107(Suppl
1): S56–S71. 2007.
|
|
22
|
Wernyj RP and Morin PJ: Molecular
mechanisms of platinum resistance: still searching for the
Achilles’ heel. Drug Resist Updat. 7:227–232. 2004.
|
|
23
|
Hou W, Chen L, Yang G, et al: Synergistic
antitumor effects of liposomal honokiol combined with adriamycin in
breast cancer models. Phytother Res. 22:1125–1132. 2008.
|
|
24
|
Choi KS, Jun JK, Park EC, et al:
Performance of different gastric cancer screening methods in Korea:
a population-based study. PLoS One. 7:e500412012.
|
|
25
|
Hainsworth JD, Johnson DH and Greco FA:
Cisplatin-based combination chemotherapy in the treatment of poorly
differentiated carcinoma and poorly differentiated adenocarcinoma
of unknown primary site: results of a 12-year experience. J Clin
Oncol. 10:912–922. 1992.
|
|
26
|
Ohtsu A, Shimada Y, Yoshida S, et al:
Phase II study of protracted infusional 5-fluorouracil combined
with cisplatinum for advanced gastric cancer: report from the Japan
Clinical Oncology Group (JCOG). Eur J Cancer. 30A:2091–2093.
1994.
|
|
27
|
Fuertes MA, Castilla J, Alonso C and Pérez
JM: Cisplatin biochemical mechanism of action: from cytotoxicity to
induction of cell death through interconnections between apoptotic
and necrotic pathways. Curr Med Chem. 10:257–266. 2003.
|
|
28
|
Brabec V: DNA modifications by antitumor
platinum and ruthenium compounds: their recognition and repair.
Prog Nucleic Acid Res Mol Biol. 71:1–68. 2002.
|
|
29
|
Brabec V and Kasparkova J: Modifications
of DNA by platinum complexes. Relation to resistance of tumors to
platinum antitumor drugs. Drug Resist Updat. 8:131–146. 2005.
|
|
30
|
Bortul R, Tazzari PL, Billi AM, et al:
Deguelin, a PI3K/AKT inhibitor, enhances chemosensitivity of
leukaemia cells with an active PI3K/AKT pathway. Br J Haematol.
129:677–686. 2005.
|
